Qube Research & Technologies (QRT)
ALNY icon

Qube Research & Technologies (QRT)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100
Closed -$27K – 3525
2025
Q1 		$27K Hold
100
– – ﹤0.01% 3192
2024
Q4 		$23.5K Buy
+100
New +$26.3K ﹤0.01% 3172

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ALNY Position: Q1 2026 in Review

Qube Research & Technologies (QRT) increased its Alnylam Pharmaceuticals (ALNY) stake by 8.2% in Q1 2026, buying an estimated $21.6M and bringing the position to 838,187 shares worth $277M. The position accounts for 0.31% of the portfolio, ranked #53.

Qube Research & Technologies (QRT) first reported a position in ALNY in Q3 2018 and has held it in 16 quarters since. The position peaked at $370M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Qube Research & Technologies (QRT) held 838,187 shares of Alnylam Pharmaceuticals worth $277M as of Q1 2026.
  • Qube Research & Technologies (QRT) bought 63,511 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $21.6M.
  • Alnylam Pharmaceuticals made up 0.31% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #53 holding.
  • Qube Research & Technologies (QRT) first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 16 quarters since.
  • Qube Research & Technologies (QRT)'s Alnylam Pharmaceuticals position peaked at $370M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.